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Open-cell carotid artery stents are associated with a higher peri-procedural stroke risk than 
closed-cell stents. However, the effect of stent design on long-term durability of carotid stenting 
(CAS) is unknown. We compared the medium- to long-term risk of restenosis and ipsilateral 
stroke between patients treated with open-cell stents versus closed-cell stents in the 
International Carotid Stenting Study (ICSS). 
Methods 
Patients with symptomatic carotid stenosis were randomized to CAS or endarterectomy and 
followed with duplex ultrasound for a median of 4.0 years. We analysed data from patients with 
completed CAS procedures, known stent design, and available ultrasound follow-up. The 
primary outcome, moderate or higher restenosis ( ≥50%) was defined as a peak systolic velocity 
of >1.3m/s on ultrasound or occlusion of the treated internal carotid artery, and analysed with 
interval-censored models.  
Results 
855 patients were allocated to CAS. 714 patients with completed CAS and known stent design 
were included in the current analysis. Of these, 352 were treated with open-cell and 362 with 
closed-cell stents. Moderate or higher restenosis occurred significantly less frequently in 
patients treated with open-cell (n=113) than closed-cell stents (n=154; 5-year risks were 35.5% 
vs. 46.0%,  unadjusted hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.53-0.88). There 
was no significant difference in the risk of severe restenosis (≥70%) after open-cell stenting 
(n=27) vs. closed cell stenting (n=43; 5-year risks: 8.6% vs. 12.7%, unadjusted HR 0.63; 95% 
CI 0.37-1.05). The risk of ipsilateral stroke beyond 30 days after treatment was similar with 




Moderate or higher restenosis after CAS occurred less frequently in patients treated with open-
cell stents than closed-cell stents. However, both stent designs were equally effective at 
preventing recurrent stroke during follow-up. 






Carotid artery stenting (CAS) is a less invasive alternative to carotid endarterectomy (CEA) for 
treatment of symptomatic carotid stenosis. Previous studies reported a higher risk of peri-
procedural stroke associated with CAS, particularly in older patients.1 Beyond the initial peri-
procedural period, CAS and CEA were equally effective at preventing recurrent stroke.2, 3 
However, data pertaining to the long-term patency and restenosis of the carotid artery after CAS 
or CEA have been inconsistent.4-8  
Various carotid stent devices, with different designs and configurations are available for CAS.  
Previous studies have shown a higher risk of peri-procedural stroke in patients treated with 
open-cell stent devices compared with those treated with closed-cell devices.9-11 The effect of 
stent design on long-term patency of the internal carotid artery (ICA) and ipsilateral stroke risk 
following CAS is currently unclear. Larger open areas between struts in open-cell stents could 
in theory be associated with a higher risk of embolization due to incomplete coverage of the 
atheromatous lesion particularly in the peri-procedural period, but also potentially in the 
medium to longer-term.10 Furthermore, open-cell and closed-cell stents have different 
mechanical properties,12, 13 which might influence the risk of residual or recurrent stenosis after 
treatment. We therefore aimed to compare the medium- to long-term risk of ICA restenosis and 
recurrent stroke between patients treated with open-cell stents versus those treated with closed-
cell stents in the International Carotid Stenting Study (ICSS).2 
Methods 
Study centres, participants, randomisation and masking 
The International Carotid Stenting Study (ICSS) included patients with atherosclerotic carotid 
stenosis associated with ipsilateral TIA or stroke symptoms within 12 months prior to 
enrolment. The trial was approved by local ethics committees for non-UK centres and by the 
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Northwest Multicentre Research Ethics Committee in the UK. All patients provided written 
informed consent to participate in the trial prior to randomisation. Details on centre 
requirements, patient eligibility criteria, randomisation and treatment have been published 
previously.2, 15, 16 In short, patients with symptomatic ≥50% carotid stenosis (according to 
NASCET criteria17), who were considered equally suitable for either procedure, were randomly 
assigned to treatment with CAS or CEA in a 1:1 ratio. Randomisation was performed by 
telephone or fax using a computerised service provided by the Oxford Clinical Trials Service 
Unit.  
Stenting procedures and follow-up 
Prior to randomisation, patients required carotid imaging with either selective digital 
subtraction angiography or concordant findings on extracranial carotid duplex ultrasound and 
non-invasive angiography (magnetic resonance angiography [MRA] or computed tomography 
angiography [CTA]). Stents and cerebral protection devices were chosen at the discretion of 
the interventionist but had to be ‘CE marked’ (Communauté Européenne) and approved by the 
Steering Committee. Stent devices used were documented at each participating centre. All 
patients received optimal medical care, and control of vascular risk factors. Pre-medication 
before CAS was discretionary, but the combination of aspirin and clopidogrel was 
recommended. The use of intraprocedural heparin was mandatory, but the exact dose was also 
discretionary. 
Patients were followed up clinically at 30 days after treatment, at 6 months after randomisation, 
and annually thereafter. Follow-up was initially planned for 5 years but was extended to 10 
years after randomisation for patients who were able and willing to continue. The protocol 
specified carotid duplex ultrasound to be done at each follow-up visit. Peak systolic velocities 
in the common carotid artery (PSV CCA), in the internal carotid artery (PSV ICA) and the end 
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diastolic velocity in the ICA (EDV ICA) on duplex ultrasound were recorded at each site and 
reported to the central trial office.  
Outcomes  
Degree of stenosis at each visit was determined centrally based on the ultrasound flow velocities 
recorded at each site, using pre-defined criteria which correlated well with the severity of 
carotid stenosis measured on catheter angiography using the NASCET method of estimating 
stenosis.17 The PSV ICA cut-off values used to quantify the severity of stenosis were >1.3 m/s 
for ≥50% stenosis, and > 2.1 m/s for ≥70% stenosis, but the EDV ICA and the PSV ICA/PSV 
CCA ratio were also considered (Table 2).8, 18 No correction was made for the presence of a 
stent or stent design when measuring stenosis.8 Ultrasound velocity measurements were not 
available from a small number of centres; in these cases, the percent stenosis reported by the 
local ultrasonographer and investigator was used.  For the purpose of this study, moderate or 
higher restenosis was defined as ≥50% stenosis or occlusion of the treated carotid artery seen 
at any time during follow-up after completion of treatment. Severe restenosis was defined as 
≥70% stenosis or occlusion. This definition of restenosis did not differentiate between residual 
stenosis present immediately after treatment and recurrent ‘true restenosis’ which developed 
over time. CAS was defined as being completed when a stent was placed across the stenosis.  
Major clinical outcome events were adjudicated by an independent end-point committee.  
Stroke was defined clinically as a rapidly developing clinical syndrome of focal retinal or 
cerebral dysfunction, lasting more than 24 hours or leading to earlier death, with no other 
apparent non-vascular cause.   
Statistical analysis 
The present analysis was performed as a per-protocol analysis and only included patients 
randomly allocated to stent treatment in whom the stenting procedure was completed, stent type 
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was known and in whom at least one post-procedural ultrasound follow-up examination was 
available. Patients who did not undergo revascularisation, those with aborted procedures, and 
those crossing over to receive endarterectomy were excluded. For analyses of restenosis, 
patients were censored at the time of any further ipsilateral revascularisation procedure during 
follow-up or at the time of their last ultrasound examination. Censoring was assumed to be non-
informative.  
Restenosis was only known to have occurred at some point between the previous ultrasound 
scan and the one showing restenosis. We therefore used methods for interval-censored data and 
time to restenosis was analysed using a generalised non-linear model, which assumes 
proportional hazards.  Based on this model the treatment effect parameter estimate can be 
interpreted as a log hazard ratio (HR).8, 18, 19 Proportionality of hazards was tested via 
interactions with follow-up time periods.  
The treatment effect p-value for restenosis was calculated using a likelihood ratio test. HRs for 
restenosis were calculated with closed-cell stents as the reference group without adjustment, as 
well as after adjustment for patient baseline characteristics which were previously identified to 
be independently associated with restenosis in ICSS.8 The cumulative incidence of restenosis 
at one and five years after CAS was calculated using the Kaplan Meier method, with the time 
to restenosis set to the mid-point between the previous normal scan and the one showing 
restenosis. Kaplan Meier plots of time to restenosis were truncated at 7 years because the 
number of patients in whom ultrasound follow-up was continued beyond this time point was 
relatively small.  
Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% CIs for 
ipsilateral stroke and stroke occurring in any territory, with closed-cell stenting as the reference 
group using all data to the end of follow-up. Kaplan-Meier estimates of cumulative risk 5 years 
after randomisation with 95% CIs were calculated. The proportionality for Cox models was 
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tested with Schoenfeld residuals and confirmed no significant departures from the 
proportionality assumption. 
All reported p-values are two-sided, with a value <0.05 considered to indicate statistical 
significance. No adjustment for multiple comparisons was made. ICSS is registered, number 
ISRCTN25337470. 
Results 
Between May 2001 and October 2008, 1713 patients were enrolled in ICSS. Of those, 855 were 
randomly assigned to stenting, and 858 to endarterectomy (Figure 1). In 764 patients the CAS 
procedure was completed. Ultrasound follow-up was performed in 740 of these 764 patients. 
In 26 patients, no information on the type of stent used was available. We therefore included 
data from 714 patients with completed CAS procedures, known stent design and available 
ultrasound follow-up data in our analysis. Of these patients, 352 were treated with an open-cell 
and 362 with a closed-cell stent. Median duration of follow-up was 4.0 years (interquartile range 
2.3-5.0), with a maximum of 10 years. Baseline characteristics of patients treated with open-
cell and closed-cell stents as well as of patients excluded from analysis because the procedure 
was aborted, stent type was unknown or no ultrasound follow-up was available are provided in 
Table 1. Patients treated with open-cell and closed-cell stents were very similar in these 
characteristics. Excluded patients differed in some of the characteristics from our analysis 
population.  
Moderate or higher restenosis occurred significantly less frequently in patients treated with 
open-cell stents (n=113)  than in patients treated with closed-cell stents (n=154; 5-year risks 
35.5% vs. 46%, unadjusted hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.53-0.88; 
Figure 2A). This difference remained after adjustment for baseline characteristics predicting 
restenosis (adjusted HR 0.58, 95% CI 0.44-0.76).  
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There was no significant difference in the incidence of severe restenosis (≥70%) or occlusion 
following open-cell (n=27) vs. closed-cell stenting (n=43; cumulative 5 year risks of 8.6% 
versus 12.7%; unadjusted HR 0.63, 95% CI: 0.37-1.05; adjusted HR 0.63, 95% CI: 0.37-1.06; 
Figure 2B). 
There was no statistically significant difference in the occurrence of ipsilateral stroke beyond 
30 days after treatment with open-cell (n=10, 5 year risk 4.6%, 95% CI 2.4-8.7) vs. closed-cell 
(n=14, 5 year risk 4.3, 95% CI 2.4-7.5) stenting (HR 0.78, 95% CI 0.35-1.75; Figure 3A), nor 
in the occurrence of stroke in any territory beyond 30 days after stenting in the 2 groups (n=17, 
5 year risk 7.4%, 95% CI 4.5-12.0 vs. n=30, 5 year risk 9.3%, 95% CI 6.3-13.5, respectively; 
HR 0.62, 95% CI 0.34-1.12; Figure 3B).  
Discussion 
In the current analysis of patients who underwent CAS in ICSS, the risk of at least moderate 
restenosis or occlusion of the treated carotid artery was significantly lower in patients treated 
with open-cell stents than in those treated with closed-cell devices over a median follow-up 
period of 4 years. However, both stent designs appeared equally effective at preventing severe 
restenosis or recurrent ipsilateral stroke during follow-up.  
Following the introduction of carotid artery stenting as a less invasive alternative to carotid 
endarterectomy for treatment of symptomatic carotid stenosis, stent design has evolved for 
optimised use in the carotid artery. Previous studies suggested that there is a higher risk of peri-
procedural stroke following open-cell compared with closed-cell CAS.9-11, 20 However, one of 
the potential advantages of open-cell stents is that they are more flexible and better suited for 
tortuous supra-aortic vessels.21 Closed-cell stents on the other hand have tighter meshes, which 
may provide better coverage of the atheromatous lesion, but are consequently more rigid. Prior 
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to conduct of this study, data pertaining to the influence of stent design on the medium- to long-
term patency of the carotid artery and efficacy in preventing recurrent stroke were limited.   
Some previous studies reported that CAS may change the mechanical characteristics of the 
vessel wall, thus rendering it less compliant and more rigid. This effect might be more 
pronounced with closed-cell stents than with open-cell stents. The change in vessel wall 
elasticity might lead to higher peak systolic blood flow velocities (PSV) in stented arteries at a 
given degree of narrowing compared with native arteries, and potentially to a higher PSV in 
arteries treated with closed-cell compared with open-cell stents. Such an effect might cause an 
apparent difference in the incidence of restenosis quantified by ultrasound alone. One 
observational study in patients without residual stenosis reported that PSVs were significantly 
higher in arteries treated with closed-cell stents compared with those treated with open-cell 
stents.21 However, PSVs were measured immediately after the CAS procedure and no 
ultrasound follow-up was performed to assess the longer-term risk of restenosis in that study. 
In contrast, a prospectively-designed sub-study of ICSS comparing duplex-ultrasound flow 
velocities with degree of stenosis  measured on computed tomography angiography (CTA) 
identified very similar optimal PSV cut-off values for moderate (≥50%) restenosis for open-
cell stents (118cm/s) and closed-cell stents (128cm/s).14 Moderate or higher restenosis on CTA 
was more common with closed-cell stents than with open-cell stents.14  
These data support the conclusion that we observed a truly higher incidence of moderate or 
higher restenosis in CAS patients treated with closed-cell stents compared with patients 
receiving open-cell stenting. We can only speculate on possible mechanisms underlying this 
difference. The more rigid, more densely-packed material in closed-cell stents compared with 
open-cell stents might lead to greater irritation of the vessel wall which in turn might stimulate 
neo-intimal hyperplasia and result in a higher rate of restenosis. This hypothesis is supported 
by the fact that most of the divergence in the incidence of restenosis between the 2 stent designs 
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occurred in the first year after treatment (Figure 2A) when neo-intimal hyperplasia is considered 
to be the key mechanism causing carotid restenosis. 22 
The Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis 
(EVA-3S) trial found no significant association between the risk of moderate or higher (≥50%) 
restenosis and stent type.23 However, this study only included 242 CAS patients and may have 
been underpowered to detect a difference. The Stent-Protected Angioplasty versus Carotid 
Endarterectomy (SPACE) study did not investigate the potential association between stent 
design and the risk of restenosis after CAS, and only one stent device (‘RX Acculink stent’), an 
open-cell device, was used throughout the Carotid Revascularization Endarterectomy vs. 
Stenting Trial (CREST).24 
With regard to stroke prevention in the medium- to long-term after the peri-procedural period, 
we found no significant differences in the risk of recurrent ipsilateral stroke or stroke in any 
territory occurring beyond 30 days after treatment between open- versus closed-cell stents. 
This study has some limitations. Velocity measurements were analysed as recorded by local 
investigators, and we were not able to review duplex images to check whether angle correction 
had been performed in all cases. However, our methodology was similar to other studies,8 and 
all duplex ultrasound follow-up examinations were performed in accordance with pre-specified 
ultrasound criteria (Table 2) in well-established vascular laboratories at the participating 
centres. Second, this was not a randomised comparison of outcomes following open-cell vs. 
closed-cell stenting and the criteria used by individual practitioners to choose one stent type 
over the other were unknown. Therefore, we cannot be certain that there were no differences in 
original plaque morphology or vascular anatomy between those who had closed-cell vs. open-
cell stenting which might have differentially influenced the risk of restenosis in one subgroup. 
However, there were no significant differences in any baseline demographic or vascular risk 
factor profiles, including stenosis severity, between patients treated with open-cell versus 
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closed-cell stents. Third, we did not reassess our entre study population with another non-
invasive imaging modality to confirm or refute our ultrasound findings. Fourth, our analysis 
may have been underpowered to detect a true difference in the risk of severe restenosis after 
open-cell compared with closed-cell stenting. 
Conclusions 
Moderate or higher restenosis occurred significantly less frequently in patients treated with 
open-cell stents compared with those treated with closed-cell stents. However, both stent 
designs were equally effective at preventing severe restenosis and recurrent stroke in the 
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Table 1 – Baseline characteristics according to stent design 






Age (years)  69.3 (8.9) 70.0 (9.1) 72.7 (9.3) 
Female sex  108/352 (30.7%) 110/362 (30.4%) 34/139 (24.5%) 
Treated hypertension  237/348 (68.1%) 249/359 (69.4%) 101/136 (74.3%) 
Systolic blood 
pressure (mmHg) 
 151 (25) 145 (22) 144 (23) 
Diastolic blood 
pressure (mmHg) 
 81 (12) 78 (12) 79 (11) 
Diabetes mellitus  73/352 (20.7%) 86/362 (23.8%) 25/139 (18.0%) 
- Non-insulin 
dependent 
 50/348 (14.4%) 64/359 (17.8%) 20/136 (14.7%) 
- Insulin 
dependent 
 23/348 (6.6%) 22/359 (6.1%) 5/136 (3.7%) 
Treated 
hyperlipidaemia 
 217/348 (62.4%) 227/359 (63.2%) 78/136 (57.4%) 
Total cholesterol 
(mmol/l) 
 4.8 (1.2) 5.0 (1.3) 4.5 (1.1) 
Current smoker  89/348 (25.6%) 87/359 (24.2%) 29/136 (21.3%) 
Ex-smoker  171/348 (49.1%) 170/359 (47.4%) 67/136 (49.3%) 
Angina in last 6 
months 
 31/348 (8.9%) 35/359 (9.7%) 17/136 (12.5%) 
Previous myocardial 
infarction 
 65/348 (18.7%) 54/359 (15.0%) 32/136 (23.5%) 
Previous CABG  52/348 (14.9%) 37/359 (10.3%) 20/136 (14.7%) 
Atrial fibrillation  19/348 (5.5%) 23/359 (6.4%) 15/136 (11.0%) 
Other cardio-embolic 
source 
 8/348 (2.3%) 7/359 (1.9%) 4/136 (2.9%) 
Cardiac failure  11/348 (3.2%) 8/359 (2.2%) 4/136 (2.9%) 
Peripheral artery 
disease 




50-69% 38/352 (10.8%) 35/362 (9.7%) 19/139 (13.7%) 




0-49% 231/350 (66.0%) 245/362 (67.7%) 89/135 (65.9%) 
 50-69% 50/350 (14.3%) 52/362 (14.4%) 26/135 (19.3%) 
 70-99% 46/350 (13.1%) 47/362 (13.0%) 12/135 (8.9%) 













16/347 (4.6%) 5/358 (1.4%) 5/135 (3.7%) 
 TIA 113/347 (32.6%) 123/358 (34.4%) 37/135 (27.4%) 
 AFX 67/347 (19.3%) 63/358 (17.6%) 18/135 (13.3%) 
 
Data are either medians (Interquartile Range [IQR]), numbers of patients/total number (%), 
or means (Standard Deviation [SD]). *Degree of stenosis reported by randomizing centre 
correlating with the measurement of stenosis used in the North American Symptomatic 
Carotid Endarterectomy Trial or an equivalent non-invasive imaging modality. † If two 
events were reported on the same day, the more severe event was recorded as the index event. 





Table 2 – Duplex ultrasound velocity criteria used for grading the degree (%) of carotid 
stenosis 
 
The degree of stenosis is expressed in values considered equivalent to the NASCET 
measurement of stenosis on catheter angiography. Velocity measurements are in meters per 
second. In cases where the flow velocity criteria spanned more than one category of stenosis, 
the higher category of stenosis was chosen if the PSV ICA and either the EDV ICA or the PSV 
ICA/CCA ratio were within the higher band. PSV – peak systolic velocity, EDV – end diastolic 








Band of stenosis 
(%) 
PSV ICA (m/s) EDV ICA (m/s) PSV ICA / PSV CCA 
0 – 29 <1.1 <0.4 <3.2 
30 – 49 1.1 – 1.3 <0.4 <3.2 
50 – 59 >1.3 – 2.1 <0.4 <3.2 
60 – 69 >1.3 – 2.1 0.4 – 1.1 3.2 – 4.0 
70 – 79 >2.1 >1.1 – 1.4 >4.0 
80 – 95 >2.1 >1.4 >4.0 
96 – 99 String Flow String Flow String Flow 





Figure 1 – Patient flow. Study flow chart depicting all patients enrolled in the International 
Carotid Stenting Study (ICSS) as well as events precluding patients from this analysis. 
Figure 2 – Moderate or higher (≥50%) restenosis or occlusion and severe (≥70%) 
restenosis or occlusion.  Figure 2: (A) Cumulative incidence of ipsilateral moderate or higher 
(≥50%) carotid restenosis or occlusion, and (B) severe (≥70%) carotid restenosis or occlusion 
after completed carotid artery stenting, estimated by life-table analysis. Error bars represent 
standard errors. Graphs stop at 7 years’ follow-up because the number of patients at risk 
beyond that time was less than 100, but analyses were based on all follow-up data (maximum 
duration of follow up was 10 years). 
Figure 3 – Ipsilateral or any post-procedural stroke (beyond 30 days after treatment). (A) 
Cumulative incidence of post-procedural ipsilateral stroke beyond 30 days after treatment, and 
(B) post-procedural stroke in any territory after completed carotid artery stenting, estimated 
by life-table analysis. Patients with any stroke within 30 days after treatment (n=44) were 
excluded from this analysis. Graphs stop at 7 years’ follow-up because the number of patients 
at risk beyond that time was less than 100, but analyses were based on all follow-up data 
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